Specialty Chemicals company Balaji Amines announced Q4FY25 & FY25 results Consolidated Q4FY25 Financial Highlights: Revenue from Operations for Q4FY25 stood at Rs 361 crore, as compared to Rs 321 crore in Q3FY25 Total volumes stood at 25,871 MT for Q4FY25 as against 24,107 MT in Q3FY25. EBITDA for Q4FY25 was Rs 68 crore, as compared to Rs 54 crore in Q3FY25 and Rs 106 crore in Q4FY24. EBITDA margin for Q4FY25 stood at 19% as against 17% in Q3FY25 and 25% in Q4FY24. PAT for Q4FY25 was Rs 40 crore as compared to Rs 31 crore in Q3FY25. Diluted EPS for Q4FY25 stood at Rs 12.36 per equity share as against Rs 10.24 in Q3FY25. Consolidated FY25 Financial Highlights: Total Income decreased by 14.4%, from Rs 1,671 crore to Rs 1,430 crore. EBITDA declined by 24.9%, from Rs 353 crore to Rs 265 crore. EBITDA Margin fell by 200 bps, from 21% to 19%. PAT dropped by 31.5%, from Rs 232 crore to Rs 159 crore. Sales Volume declined by 4.5%, from 1,09,320 MT to 1,04,393 MT. Cash PAT decreased by 27.5%, from Rs 284 crore to Rs 206 crore. Standalone Q4FY25 Financial Highlights: Revenue from Operations for Q4FY25 stood at Rs 327 crore, as compared to Rs 305 crore in Q3FY25 Total volumes stood at 24,047 MT for Q4FY25 as against 23,447 MT in Q3FY25. EBITDA for Q4FY25 was Rs 64 crore, as compared to Rs 57 crore in Q3FY25 and Rs 95 crore in Q4FY24 EBITDA margin for Q4FY25 stood at 20% as against 19% in Q3FY25 and 25% in Q4FY24. PAT for Q4FY25 was Rs 40 crore as compared to Rs 36 crore in Q3FY25. Diluted EPS for Q4FY25 stood at Rs 12.22 per equity share as against Rs 11.01 in Q3FY25. Standalone FY25 Financial Highlights: Total Income decreased by 4.6%, from Rs 1,359 crore to Rs 1,296 crore. EBITDA declined by 6.7%, from Rs 267 crore to Rs 249 crore. EBITDA Margin reduced by 100 bps, from 20% to 19%. PAT decreased by 8.8%, from Rs 171 crore to Rs 156 crore. Cash PAT dropped by 4.2%, from Rs 213 crore to Rs 204 crore. Sales Volume increased by 1.5%, from 96,596 MT to 98,086 MT. On the performance, D. Ram Reddy, Managing Director, commented, “During Q4FY25, our business performance showed improvement compared to the rest of the financial year, supported by favorable global macroeconomic conditions. As volume uptake gradually increases, we expect EBITDA and PAT margins to improve in line with broader industry recovery trends. However, geopolitical tensions and tariff-related challenges across global markets may continue to impact growth across several sectors in which we operate. These factors have weighed on domestic demand, but we anticipate that better utilization of expanded capacities will support margin recovery in the coming quarters. Pharmaceutical sector demand remained steady, contributing to base volumes, while the agrochemical segment exhibited volatility during the quarter. We continue to make progress on our strategic capex initiatives, including Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether projects, which are moving forward as planned. On the sustainability front, we are pleased to announce that our 6 MW AC Solar Power Plant was commissioned on 2 nd April, 2025. The plant is being brought online in a phased manner under Grid Connectivity, and the power generated will be utilized for captive consumption. Looking ahead, we remain focused on enhancing operational efficiencies, managing input costs and expanding our product portfolio to deliver sustained value to all stakeholders.” Result PDF
Specialty Chemicals company Balaji Amines announced Q3FY25 results Revenue from Operations for Q3FY25 stood at Rs 321 crore, as compared to Rs 356 crore in Q2FY25. Total volumes stood at 24,097 MT for Q3FY25 as against 26,348 MT in Q2FY25. For Q3FY25: Amines volumes stood at 7,515 MT. Amines Derivatives volumes stood at 8,809 MT. Specialty Chemicals volumes stood at 7,773 MT. EBITDA for Q3FY25 was Rs 54 crore, as compared to Rs 70 crore in Q2FY25 and Rs 83 crore in Q3FY24. EBITDA margin for Q3FY24 stood at 17% as against 20% in Q2FY25 and 21% in Q3FY24. PAT for Q3FY25 was Rs 31 crore as compared to Rs 41 crore in Q2FY25. Diluted EPS for Q3FY25 stood at Rs 10.24 per equity share as against Rs 12.65 in Q2FY25. D. Ram Reddy, Managing Director, said: “During Q3FY25, our financial and business performance remained stable despite the challenges posed by global macroeconomic conditions. However, as volume uptake gradually increases, EBITDA and PAT margins are expected to improve in line with industry recovery. The resurgence in domestic demand, along with positive trends in international markets, is driving this momentum. Additionally, the utilization of expanded capacities will contribute to margin enhancement, as some of our products progress through the final approval stages with end-user industries. This progress is further supported by our ongoing investments in key projects, reinforcing our commitment to operational excellence. Electronic Grade DMC, Propylene Glycol Pharma Grade and Dimethyl Ether projects are progressing well, aligning with our strategic growth objectives. These initiatives are designed to strengthen our market presence, enhance product offerings, and meet the evolving needs of our customers. Looking ahead, we maintain a positive outlook for long-term opportunities, anticipating growth and increased prospects during the FY26. Our focus on inherent strengths and competencies positions us as a leading force in Amines and Specialty Chemicals, guiding us through market complexities towards greater excellence.” Result PDF
Specialty Chemicals company Balaji Amines announced Q2FY25 results Revenue from Operations for Q2FY25 stood at Rs 356 crore, as compared to Rs 393 crore in Q1FY25 Total volumes stood at 26,348 MT for Q2FY25 as against 28,071 MT in Q1FY25. For Q2FY25. Amines volumes stood at 7,616 MT. Amines Derivatives volumes stood at 8,685 MT. Specialty Chemicals volumes stood at 10,046 MT EBITDA for Q2FY25 was Rs 70 crore, as compared to Rs 74 crore in Q1FY25. EBITDA margin for Q2FY24 stood at 20% as against 19% in Q1FY25. PAT for Q2FY25 was Rs 41 crore as compared to Rs 46 crore in Q1FY25. Diluted EPS for Q2FY25 stood at Rs 12.65 per equity share as against Rs 13.36 in Q1FY25. On a standalone basis, we are a zero-debt company. D. Ram Reddy, Managing Director, said, “In the Q2 quarter, we reported a revenue of Rs 356 crore, achieving an EBITDA margin of 20%. This marks a 110-basis-point improvement over last quarter, reflecting our focus on higher margin products amid a challenging industry environment. While the broader market experienced pressure in Q2, both the API and agrochemical looks promising over a long term, and we are well-positioned to seize these future opportunities. With our expanded capacities and a sharpened focus on operational efficiency, we are confident in our ability to drive sustainable growth in the coming quarters. Our recent developments demonstrate significant progress in expanding our production capacity. With the successful commencement of Methylamines production at Unit-IV, our total annual installed capacity has increased from 48,000 MT to 88,000 MT across all three units. Additionally, Unit-I and Unit-III have achieved BIS Certification for 'Morpholine,' strengthening our quality standards and making us the only BIS-certified Morpholine manufacturer in India. Projects in Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether are also advancing well, reflecting our commitment to operational excellence. As we look forward, our strong foundation in core capabilities positions us well to navigate industry dynamics and capture growth opportunities. With a clear focus on our strengths, we are set to advance as a leader in Amines and Specialty Chemicals." Result PDF
Speciality Chemicals company Balaji Amines announced Q4FY24 results: Financial Highlights: Revenue from Operations for Q4FY24 stood at Rs 423 crore, as compared to Rs 392 crore in Q3FY24. Total volumes stood at 27,984 MT for Q4FY24 as against 26,903 MT in Q3FY24. For Q4FY24, Amines volumes stood at 8,910 MT Amines Derivatives volumes stood at 9,676 MT Specialty Chemicals volumes stood at 9,398 MT EBITDA for Q4FY24 was Rs 106 crore, as compared to Rs 83 crore in Q3FY24. EBITDA margin for Q4FY24 stood at 25% as against 21% in Q3FY24. PAT for Q4FY24 was Rs 72 crore as compared to Rs 56 crore in Q3FY24. Diluted EPS for Q4FY24 stood at Rs 21.00 per equity share as against Rs 15.24 in Q3FY24. On a standalone basis, it is a zero-debt company. On the performance, D. Ram Reddy, Managing Director, commented, “In Q4 & FY24, our financial and business highlights indicate a positive trajectory, with higher volume uptake, improved EBITDA and PAT margins driven by stabilised input costs(on both raw materials and utilities fronts) and a settling industry scenario. The rebound in domestic demand, coupled with encouraging international market trends, is contributing to this momentum and enhancing our margins. Recent developments include the successful commencement of n-Butylamines production at Unit-IV, boasting an annual installed capacity of 15,000 MT. Furthermore, Unit-I and Unit-III have received BIS Certification for 'Morpholine,' enhancing our product quality standards. Both Methylamine and Dimethyl Ether projects are progressing well, showcasing our commitment to operational excellence. Looking ahead, we maintain a positive outlook for long-term opportunities, anticipating growth and increased prospects in the fiscal year 2024- 25. Our focus on inherent strengths and competencies positions us as a leading force in Amines and Specialty Chemicals, guiding us through market complexities towards greater excellence.” Result PDF